Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      • Home
      • Meghna A Singhania

      Articles By : Meghna A Singhania

      CDSCO denies approval for Akums Acid reflux FDC in Capsule form

      CDSCO denies approval for Akums Acid reflux FDC in Capsule form

      Meghna A Singhania8 May 2019 10:15 AM IST
      New Delhi: In order to expand its portfolio, Akum Drugs & Pharmaceuticals Ltd. presented before the Subject Experts Committee (SEC) functional...
      NPPA to revise ceiling price of Silver Sulphadiazine cream 1 pc; direct manufacturers to furnish data

      NPPA to revise ceiling price of Silver Sulphadiazine cream 1 pc; direct manufacturers to furnish data

      Meghna A Singhania7 May 2019 4:52 PM IST
      New Delhi: Through a recent Office Memorandum, National Pharmaceutical Pricing Authority (NPPA) has informed that it will soon revise the ceiling...
      DOP Order: NPPA refixes retail price of Trilosar 6.25, 12.5

      DOP Order: NPPA refixes retail price of Trilosar 6.25, 12.5

      Meghna A Singhania6 May 2019 11:23 AM IST
      New Delhi: Through a recent notification, the government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail...
      CDSCO Committee rejects proposal for additional Indications of Dapaglofizin

      CDSCO Committee rejects proposal for additional Indications of Dapaglofizin

      Meghna A Singhania5 May 2019 12:52 PM IST
      New Delhi: British-Swedish multinational drugmaker, AstraZeneca's stride to win approval from the Indian drug regulators for the additional...
      NPPA fixes retail price of 20 drugs including FDCs for Blood pressure control, dual antiplatelet

      NPPA fixes retail price of 20 drugs including FDCs for Blood pressure control, dual antiplatelet

      Meghna A Singhania4 May 2019 12:31 PM IST
      New Delhi: Through a recent notification, the government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail...
      Biocon, Lupin, Wockhardt, Cadila Healthcare lose Insurance Battle in Delhi High Court

      Biocon, Lupin, Wockhardt, Cadila Healthcare lose Insurance Battle in Delhi High Court

      Meghna A Singhania3 May 2019 1:50 PM IST
      Mumbai:In a court setback to many big drugmakers in India, a petition filed by pharma majors including Biocon, Wockhardt, Lupin and Cadila Healthcare...
      JnJ hip implants: CDSCO orders compensation of over Rs 2 crore for 2 more patients

      JnJ hip implants: CDSCO orders compensation of over Rs 2 crore for 2 more patients

      Meghna A Singhania2 May 2019 11:23 AM IST
      With these two cases, the Central Drugs Standard Control Organisation (CDSCO) has so far ordered compensation to four patients, based on the...
      Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen

      Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen

      Meghna A Singhania30 April 2019 10:16 AM IST
      Glenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.Mumbai: In a major relief to diabetics, Glenmark...
      Presence of Formaldehyde in JnJ baby shampoo; company junks Rajasthan report

      Presence of Formaldehyde in JnJ baby shampoo; company junks Rajasthan report

      Meghna A Singhania29 April 2019 10:00 AM IST
      Based on the report of the Drug Testing Laboratory in Jaipur, the National Commission for Protection of Child Rights (NCPCR) has written to the chief...
      Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

      Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

      Meghna A Singhania28 April 2019 12:04 PM IST
      Vadodara: Stressing on the authenticity of medical treatment provided by a medical practitioner, a consumer court has made an incisive observation and...
      CDSCO to hire 754 Regulatory Officers especially to regulate Medical Devices in country:DTAB

      CDSCO to hire 754 Regulatory Officers especially to regulate Medical Devices in country:DTAB

      Meghna A Singhania27 April 2019 3:00 PM IST
      New Delhi: With the various controversies relating to medical devices taking the limelight, the Government is looking forward to recruiting 754...
      Ban on online sale of medicines: Delhi HC issues notice to Centre, e-pharmacies on contempt plea

      Ban on online sale of medicines: Delhi HC issues notice to Centre, e-pharmacies on contempt plea

      Meghna A Singhania25 April 2019 2:21 PM IST
      The council claimed that the e-pharmacies in willful disobedience of the order passed by the high court are selling medicines online.New Delhi: The...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok